论文部分内容阅读
本文对40例曾经小剂量干扰素治疗、疗程达6个月的慢性乙肝患者进行治后6～20个月的追踪观察。从HBV标志物阴转率来看,抗病毒远期疗效结果为HBeAg治前19例阳性中,12例阴转(63.1％),其中6例并出现抗-HBe转阳。DNA-P治前3例阳性中,2例阴转(66.6％)。HBcAg治前2例阳性者也阴转。HBV-DNA治前3例阳性者仅一例阴转。HBsAg 39例阳性中,7例阴转(17.9％)。其中HBeAg及DNA-p阴转率较突出,分别为63.1％及66.6％。再从抗病毒综合反应来看,远期总有效率达57.5％(23/40),其中3例在治后14、15及20个月观察时:HBsAg、HBeAg、HBcAg、DNA-P及HBV-DNA均阴性。对照组20例HBsAg、HBeAg及DNA-P阴转率分别为0％、22.2％及0％。可见并非自然阴转,而是药物作用所致。由此认为小剂量干扰素对抗慢性乙肝病毒远期疗效是可取的,值得深入研究。
In this paper, 40 cases of patients with chronic hepatitis B who had been treated with low-dose interferon for 6 months were followed up for 6 to 20 months. In terms of the negative rate of HBV markers, the long-term results of antiviral therapy were positive in 19 cases before HBeAg treatment, and 12 cases were negative (63.1%) in 6 cases, and anti-HBe was found in 6 cases. In the first 3 cases of DNA-P, 2 cases were negative (66.6%). HBcAg positive 2 patients before the positive also negative. HBV-DNA in the first three cases were positive only one negative. In 39 cases of HBsAg positive, 7 cases were negative (17.9%). The negative conversion rates of HBeAg and DNA-p were 63.1% and 66.6% respectively. From the comprehensive antiviral response point of view, the long-term total effective rate was 57.5% (23/40), of which 3 were observed at 14,15 and 20 months after treatment: HBsAg, HBeAg, HBcAg, DNA-P and HBV -DNA were negative. The control group of 20 cases of HBsAg, HBeAg and DNA-P negative conversion rates were 0%, 22.2% and 0%. Visible is not natural overcast, but due to the role of drugs. Therefore, low-dose interferon against long-term efficacy of chronic hepatitis B virus is desirable, it is worth further study.